Jes Dietrich
Copenhagen, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications
Post-exposure vaccine protection of CTH522/CAF®01 against reinfection with Chlamydia trachomatis requires Th1/Th17 but not Th2-immunity.
Journal: NPJ vaccines
Published: December 19, 2024
Intradermal administration of novel particulate Chlamydia trachomatis vaccine candidates drives protective immune responses.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: June 25, 2024
Multimodal mucosal and systemic immune characterization of a non-human primate trachoma model highlights the critical role of local immunity during acute phase disease.
Journal: PLoS neglected tropical diseases
Published: January 31, 2024
Author Correction: Co-adjuvanting DDA/TDB liposomes with a TLR7 agonist allows for IgG2a/c class-switching in the absence of Th1 cells.
Journal: NPJ vaccines
Published: January 11, 2024
An investigation of trachoma vaccine regimens by the chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02): a phase 1, double-blind trial.
Journal: The Lancet. Infectious diseases
Published: November 13, 2023
Multi-component prime-boost Chlamydia trachomatis vaccination regimes induce antibody and T cell responses and accelerate clearance of infection in a non-human primate model.
Journal: Frontiers in immunology
Published: September 29, 2022
Chlamydia trachomatis vaccine development - a view on the current challenges and how to move forward.
Journal: Expert review of vaccines
Published: August 25, 2022
Last Updated: 09/26/2026